Atellica® IM Prostate-Specific Antigen (PSA) Assay
FDA premarket approval P950021/S025 · decided 2022-03-29
Approval details
- PMA number
- P950021
- Supplement
- S025
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- Atellica® IM Prostate-Specific Antigen (PSA) Assay
- Generic name
- Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions
- Applicant
- Siemens Healthcare Diagnostics
- Date received
- 2022-03-22
- Decision date
- 2022-03-29
- Days to decision
- 7 days
- Decision code
- OK30
- Product code
- MTG
- Advisory committee
- Immunology
- Expedited review
- No
- Location
- East Walpole, MA
- Statement
- Manufacture an instrument component at another location.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.